Clinical Impact of New Data From HIV Glasgow 2020 Virtual

October 5-8, 2020/Virtual
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including new data on current ART options, investigational ART strategies, and comorbidities.
Monica Gandhi, MD, MPH
Renslow Sherer, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 422 KB
Released: October 23, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Janssen Therapeutics, Division of Janssen Products, LP

Related Content

Clinical Care Options (CCO) presents patient advocate and patient discussing the importance of overcoming local barriers to HIV care for women

person default Angelina Namiba Released: August 5, 2022

Safety and efficacy of broadly neutralizing antibody VRC01 with early ART in infants with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

ANDES: Wk 48 safety and efficacy of generic darunavir/ritonavir + lamivudine for initial HIV treatment, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 5, 2022

Safety and efficacy of 24-wk oral regimens for pulmonary rifampicin-resistant TB in persons with HIV, reported by Clinical Care Options (CCO) from AIDS 2022

Released: August 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings